Skip to main content
Premium Trial:

Request an Annual Quote

Open Medicine Foundation Commits $1.2M to Fund ME/CFS Research

NEW YORK (GenomeWeb) – The Open Medicine Foundation (OMF) announced today that it has committed $1.2 million to fund the first year of operations at the newly established ME/CFS Collaborative Research Center at Stanford University.

According to the OMF, the center is focused on investigating the molecular basis of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), as well as developing new diagnostics and treatments for the conditions. Its initial projects involve sequencing single T cells to understand the immunological basis of ME/CFS; analyzing sets of genomic and other omics data to define patient subgroups, uncover disease biomarkers, and identify potential drug targets; and developing a blood-based ME/CFS diagnostic that can also be used as a reporter in drug screening.

The OMF added that the ME/CFS Collaborative Research Center is being led by Stanford's Ron Davis and includes investigators from the Stanford Genome Technology Center, Yale University, Massachusetts General Hospital, Integrative Bioinformatics, the European Molecular Biology Laboratory, and the University of California, San Diego.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.